FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test - POCTRN
The Point-of-Care Technology Research Network develops technologies with clinical applications using a network model that enhances complementary strengths and builds multidisciplinary partnerships.
Center news
FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test
Today, the FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away.
Although a cure for hepatitis C is available, many people with the potentially deadly disease are not aware that they have it and do not receive treatment. This is partly because hepatitis C testing has been a lengthy process before results are available and requires follow-up appointments. But now, it will be possible to obtain a test result and start a course of treatment at the same health visit.
Atlanta Center for Microsystems Engineered Point-of-Care Technologies
Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases
Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern
Center for Advancing Point of Care in Heart, Lung, Blood, and Sleep Diseases
Center for Point of Care Technologies for Nutrition, Infection, and Cancer in Global Health at Cornell University
The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care
Our partners
National Heart, Lung, and Blood Institute
National Institute of Allergy and Infectious Diseases
National Center for Complementary and Integrative Health
Fogarty International Center
Office of Behavioral and Social Sciences Research
Office of AIDS Research
Office of Disease Prevention